Aflibercept (Eylea)

Eylea (aflibercept) is covered only for the listed FDA‑approved retinal indications (neovascular AMD, macular edema after RVO, DME, DR with DME) and one approved off‑label compendial use (macular choroidal neovascularization); use for indications not listed is excluded. Approval (up to 12 months) requires documentation of a covered diagnosis, absence of ocular/periocular infection and active intraocular inflammation, and adherence to the indication‑specific intravitreal dosing regimens.

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.